Evidence map›Paper›PMID 36993520›Full record

ArticleResearch square2023

Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibiting moderate effect on normal stem cells growth.

Arshak Alexanian, Heidi Stoellinger, Virginea De Araujo Farias, Alfredo Quinones-Hinojosa

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Arshak AlexanianCell Reprogramming & Therapeutics LLC.
Heidi StoellingerCell Reprogramming & Therapeutics LLC.
Virginea De Araujo FariasMayo Clinic.
Alfredo Quinones-HinojosaMayo Clinic.
WinnMed · US

Funding

Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapyR43CA221490 · NCI · CELL REPROGRAMMING AND THERAPEUTICS, LLC · PI ALEXANIAN, ARSHAK R, QUINONES-HINOJOSA, ALFREDO · 2018 to 2018
$300k
NCI NIH HHS R43 CA221490
6 · The paper itself

Abstract

Glioblastomas (GBM), also known as glioblastoma multiforme, are the most aggressive type of brain cancers. Currently, there is no real treatment for GBM and thus there is a compelling need for new therapeutic strategies for such type of cancers. Recently, we demonstrated that specific combinations of epigenetic modifiers significantly affect the metabolism and proliferation rate of two most aggressive GBM cell lines D54 and U-87. Importantly, these combinations exhibited minimal effect on normal stem cells growth. In this study we demonstrated that the combinations of modulators of histone and DNA covalent modifying enzymes that synergistically suppress D54 and U87 cell lines growth, also impair the viability of a patient freshly-derived GBM stem cell line. These data suggest that epigenetic modifiers alone or in specific combinations exhibit cytotoxic effect on established and low passage patient derived GB cell lines and thus could be a promising therapeutic approach for such type of brain cancers.

Identifiers

PMID36993520
PMCPMC10055614
OpenAlexW4327939555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.